deltatrials

Heart failure Trials in Passo Fundo, Brazil

Conditions / Heart failure / Passo Fundo, Brazil

Clinical trials for Heart failure investigate a range of treatment strategies and patient populations.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT02111564 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients COMPLETED PHASE3
NCT03057951 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) COMPLETED PHASE3
NCT03315143 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk TERMINATED PHASE3
NCT03057977 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) COMPLETED PHASE3
NCT06935370 A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart RECRUITING
NCT06424288 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure RECRUITING
NCT01877915 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure COMPLETED PHASE3
NCT06008197 A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients RECRUITING
NCT02929329 Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction COMPLETED PHASE3
NCT03521934 Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) TERMINATED PHASE3

Related Pages